Navigation Links
Stem cell mobilization therapy appears to be ineffective in repairing damage caused by heart attack

Therapy that involved bone marrow stem cells did not improve cardiac function in patients following a heart attack, according to a study in the March 1 issue of JAMA.

There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies. Granulocyte colony-stimulating factor (G-CSF, a growth-factor protein) induces mobilization of bone marrow stem cells, according to background information in the article.

Dietlind Zohlnhöfer, M.D., of the Technische Universität, Munich, Germany, and colleagues conducted a randomized, double-blind, placebo-controlled study (REVIVAL-2) to assess the value of G-CSF treatment in a large group of patients following a heart attack. The 114 patients, diagnosed with ST-segment elevation acute myocardial infarction (a certain pattern on an electrocardiogram indicating a heart attack), had successful reperfusion (restoration of blood flow) to the heart by percutaneous coronary intervention (procedures such as angioplasty in which a catheter-guided balloon is used to open a narrowed coronary artery) within 12 hours after onset of symptoms. Patients were randomly assigned to receive by injection either a daily dose of 10 µg/kg of G-CSF or placebo (an inactive substance) for 5 days. The patients were treated between February 2004 and February 2005.

Treatment with G-CSF produced a significant mobilization of bone marrow stem cells. The researchers found that this did not alter infarct size (area of damage) or left ventricular function after a heart attack. "Moreover, in contrast to other studies, no increase in the risk of restenosis (narrowing again of an artery after treatment) or major adverse cardiac events was observed with G-CSF treatment," the authors write.

"The REVIVAL-2 trial had a cohort that was larger than all 3 previous trials taken together and had a relatively long follow-up period based on sensitive assessment methods of left ventricular function and infarct size. In conclusion, use of G-CSF therapy to mobilize bone marrow–derived stem cell does not improve left ventricular recovery in patients with acute myocardial infarction after successful mechanical reperfusion," they write.


'"/>

Source:JAMA and Archives Journals


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2019)... ... August 19, 2019 , ... Since ... use of ultra-thin two dimensional slices which are placed on microscope slides, stained ... complex tissues and complicated features such as vasculature and thus researchers in the ...
(Date:8/14/2019)... JUPITER, Fla. (PRWEB) , ... August 14, 2019 ... ... scheduled to broadcast 4Q/2019, will explore how developments in microbiome therapeutics are helping ... your local listings for more information. , Advancements will educate about the DECODE.DESIGN.CURE™ ...
(Date:8/14/2019)... ... ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests that ... Inc. 500|5000 list of fastest growing private companies, in the first year the ... generating revenue by March 31, 2015. Ranking in the list is determined by the ...
Breaking Biology News(10 mins):
(Date:9/17/2019)... ... 2019 , ... Tucker, a Labrador retriever, was just a puppy when he ... and lame on his right hip and elbow. At one year of age, Tucker ... case the vet had seen.” He was prescribed pain medications, both oral and injectable, ...
(Date:9/17/2019)... ... September 16, 2019 , ... When a lot of researchers think of Visikol, ... complete 3D characterization of tissues through the use of confocal and light sheet microscopy. ... and advanced cell culture focused contract research organization and today offers 3D tissue ...
(Date:9/11/2019)... PRUSSIA, Pa. (PRWEB) , ... September 09, 2019 ... ... problems for life sciences companies and government agencies, announced that its president and ... invitation-only group of successful business leaders. , The Forbes Council accepted Gallivan based ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... solutions for drugs, biologics, gene therapies, and consumer health products, today announced that ... held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18-19, ...
Breaking Biology Technology: